Annual SGA
$31.09 M
-$1.35 M-4.15%
December 31, 2023
Summary
- As of February 8, 2025, OVID annual SGA is $31.09 million, with the most recent change of -$1.35 million (-4.15%) on December 31, 2023.
- During the last 3 years, OVID annual SGA has risen by +$455.00 thousand (+1.49%).
- OVID annual SGA is now -16.51% below its all-time high of $37.23 million, reached on December 31, 2021.
Performance
OVID SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$5.54 M
-$2.56 M-31.59%
September 30, 2024
Summary
- As of February 8, 2025, OVID quarterly SGA is $5.54 million, with the most recent change of -$2.56 million (-31.59%) on September 30, 2024.
- Over the past year, OVID quarterly SGA has dropped by -$2.15 million (-27.90%).
- OVID quarterly SGA is now -64.41% below its all-time high of $15.58 million, reached on March 31, 2021.
Performance
OVID Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$1.14 B
-$32.50 M-2.93%
September 30, 2024
Summary
- As of February 8, 2025, OVID TTM SGA is -$1.14 billion, with the most recent change of -$32.50 million (-2.93%) on September 30, 2024.
- Over the past year, OVID TTM SGA has dropped by -$1.17 billion (-3778.65%).
- OVID TTM SGA is now -3084.41% below its all-time high of -$35.91 million.
Performance
OVID TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
OVID Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4.2% | -27.9% | -3778.7% |
| 3 y3 years | +1.5% | -27.9% | -3778.7% |
| 5 y5 years | +62.4% | -27.9% | -3778.7% |
OVID Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -16.5% | at low | -43.9% | at low | -101.0% | at low |
| 5 y | 5-year | -16.5% | +61.5% | -64.4% | +7.4% | -101.0% | at low |
| alltime | all time | -16.5% | +372.6% | -64.4% | +114.2% | -3084.4% | at low |
Ovid Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $5.54 M(-31.6%) | $28.50 M(-4.2%) |
| Jun 2024 | - | $8.10 M(+13.1%) | $29.77 M(-0.5%) |
| Mar 2024 | - | $7.17 M(-6.8%) | $29.91 M(-3.8%) |
| Dec 2023 | $31.09 M(-4.2%) | $7.69 M(+13.0%) | $31.09 M(+3.4%) |
| Sep 2023 | - | $6.80 M(-17.5%) | $30.06 M(-2.7%) |
| Jun 2023 | - | $8.25 M(-1.1%) | $30.89 M(-0.0%) |
| Mar 2023 | - | $8.34 M(+25.2%) | $30.89 M(-4.7%) |
| Dec 2022 | $32.43 M(-12.9%) | $6.66 M(-12.7%) | $32.43 M(-4.7%) |
| Sep 2022 | - | $7.63 M(-7.6%) | $34.03 M(+2.6%) |
| Jun 2022 | - | $8.26 M(-16.4%) | $33.16 M(+5.2%) |
| Mar 2022 | - | $9.88 M(+19.6%) | $31.54 M(-15.3%) |
| Dec 2021 | $37.23 M(+21.6%) | $8.26 M(+22.2%) | $37.23 M(-5.5%) |
| Sep 2021 | - | $6.76 M(+2.0%) | $39.38 M(-1.7%) |
| Jun 2021 | - | $6.63 M(-57.4%) | $40.06 M(-1.2%) |
| Mar 2021 | - | $15.58 M(+49.6%) | $40.54 M(+32.3%) |
| Dec 2020 | $30.63 M | $10.41 M(+39.9%) | $30.63 M(+20.7%) |
| Sep 2020 | - | $7.44 M(+4.7%) | $25.38 M(+9.8%) |
| Jun 2020 | - | $7.11 M(+25.4%) | $23.11 M(+14.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $5.67 M(+9.8%) | $20.20 M(+4.9%) |
| Dec 2019 | $19.25 M(+0.6%) | $5.16 M(-0.1%) | $19.25 M(+3.5%) |
| Sep 2019 | - | $5.17 M(+22.9%) | $18.59 M(+3.0%) |
| Jun 2019 | - | $4.21 M(-10.8%) | $18.06 M(-4.7%) |
| Mar 2019 | - | $4.72 M(+4.7%) | $18.95 M(-1.2%) |
| Dec 2018 | $19.14 M(+27.3%) | $4.51 M(-2.7%) | $19.18 M(+0.9%) |
| Sep 2018 | - | $4.63 M(-9.1%) | $19.01 M(+6.3%) |
| Jun 2018 | - | $5.09 M(+2.8%) | $17.89 M(+5.2%) |
| Mar 2018 | - | $4.96 M(+14.3%) | $17.01 M(+13.1%) |
| Dec 2017 | $15.04 M(+16.1%) | $4.33 M(+23.5%) | $15.04 M(+5.2%) |
| Sep 2017 | - | $3.51 M(-16.7%) | $14.30 M(+2.8%) |
| Jun 2017 | - | $4.21 M(+41.5%) | $13.90 M(+4.3%) |
| Mar 2017 | - | $2.98 M(-17.2%) | $13.34 M(+3.0%) |
| Dec 2016 | $12.95 M(+96.8%) | $3.60 M(+15.5%) | $12.95 M(+38.5%) |
| Sep 2016 | - | $3.12 M(-14.5%) | $9.35 M(+50.0%) |
| Jun 2016 | - | $3.65 M(+40.9%) | $6.23 M(+140.9%) |
| Mar 2016 | - | $2.59 M | $2.59 M |
| Dec 2015 | $6.58 M | - | - |
FAQ
- What is Ovid Therapeutics annual SGA?
- What is the all time high annual SGA for Ovid Therapeutics?
- What is Ovid Therapeutics annual SGA year-on-year change?
- What is Ovid Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Ovid Therapeutics?
- What is Ovid Therapeutics quarterly SGA year-on-year change?
- What is Ovid Therapeutics TTM SGA?
- What is the all time high TTM SGA for Ovid Therapeutics?
- What is Ovid Therapeutics TTM SGA year-on-year change?
What is Ovid Therapeutics annual SGA?
The current annual SGA of OVID is $31.09 M
What is the all time high annual SGA for Ovid Therapeutics?
Ovid Therapeutics all-time high annual SGA is $37.23 M
What is Ovid Therapeutics annual SGA year-on-year change?
Over the past year, OVID annual SGA has changed by -$1.35 M (-4.15%)
What is Ovid Therapeutics quarterly SGA?
The current quarterly SGA of OVID is $5.54 M
What is the all time high quarterly SGA for Ovid Therapeutics?
Ovid Therapeutics all-time high quarterly SGA is $15.58 M
What is Ovid Therapeutics quarterly SGA year-on-year change?
Over the past year, OVID quarterly SGA has changed by -$2.15 M (-27.90%)
What is Ovid Therapeutics TTM SGA?
The current TTM SGA of OVID is -$1.14 B
What is the all time high TTM SGA for Ovid Therapeutics?
Ovid Therapeutics all-time high TTM SGA is -$35.91 M
What is Ovid Therapeutics TTM SGA year-on-year change?
Over the past year, OVID TTM SGA has changed by -$1.17 B (-3778.65%)